Dr. Binayak Kumar

About

He completed his Master's Degree in Biotechnology from the University of Hyderabad and his Doctorate in Life Sciences after receiving his CSIR-NET qualification in 2010. He received his doctoral degree from Shiv Nadar University, Greater Noida, U.P. (2017). He then started his research ICMR-National Institute of Cancer Prevention and Research, Noida as an ICMR-Postdoctoral Fellow from April-2018 for two years 2 months. Then, He joined at the same place of ICMR as DHR-Young Scientist funded by Department of Health Research, India worked for 3 years till Aug-2023. His area of expertise is molecular oncology (Breast Cancer and Colorectal Cancer) addressing molecular mechanisms of therapy resistance in cancer via exploring genome and proteome profiles.

Experience

• 5.2 years of post-doctoral experience at ICMR-National Institute of Cancer Prevention and Research, India (2018-2023). 
• 12 years of research experience
   

Qualification

• Ph.D.

Award & Recognition

• DHR-Young Scientist, Division of Molecular Oncology, ICMR-National Institute of Cancer Prevention and Research (NICPR). Project title “Role of SOX2, OCT4, KLF4 and NANOG genes in therapy resistance against multi-kinase inhibitors and their post-transcriptional regulation in Breast cancer” Funded by Department of Health Research (DHR). August-2020 to Aug-2023.
• ICMR-Post-doctoral Fellow, Division of Molecular Oncology, National Institute of Cancer Prevention and Research (NICPR). Project title “To Investigate the cellular mechanisms involved in developing resistance to abemaciclib and palbociclib in Er, PR +ve and Her-2–ve breast cancer” Funded by Indian Council of Medical Research (ICMR), India. April-2018 to June-2020.
• PhD, Department of life Sciences, Shiv Nadar University, India. Thesis Title “Cellular mechanisms involved in developing resistance against multi-kinase inhibitors in colorectal cancer.” Funded by Shiv Nadar University. August. 2012 - December. 2017.
• Junior Research Fellow, Institute of Liver and Biliary Sciences, New Delhi, India. DBT funded Project title “To identify the role of notch signaling pathway in the Hepatitis-B virus induced Hepatocellular carcinoma.” Funded by DBT. February. 2011 – December. 2011.
• Qualified GATE (Graduate Aptitude Test in ngineering) in Life Sciences in 2010. 
• Qualified National Eligibility Test (NET) in “Life Science” conducted by University Grant Commission (UGC) and Council of Scientific & Industrial Research (CSIR) 2010.)
   

Research

• Efficient and Stereoselective Synthesis of Sugar Fused PyranoPyranones as Anticancer Agents" Authors: Kumar, Sandeep; Sahu, Ram Krishna; Kumari, Priti;  Maity, Jyotirmoy; Kumar, Binayak; Chhatwal, Rajni Johar; Prasad, Ashok K. RSC Advance (Accepted) IF: 4.02
• B. Kumar, P. Prasad, R. Singh, R. K. Sahu, A. Singh, S. K. M. Jayadev and S. Hedau, “Role of Identified Proteins in CDK4/6 Inhibitor-Resistant Breast Cancer Cell Lines' Proteome Profiles” Mol. Omics, 2023, Accepted Manuscript , DOI: 10.1039/D2MO00285J. IF 4.2
•  Ragini, Amrita Singh#, Binayak Kumar#, Soni Kumari, Ram krishna sahu, Suresh Hedau “Potantial of dual drug deliversy systems: MOF as hybrid nanocarrier for dual drug devliversy in cancer treatment” Chemistry Select May-2022 Review (# Equal contribution) (Accepted) IF 2.5
•  Ashish Chalana, Ramesh Karri, Rakesh Rai, Binayak Kumar, Kunal Jha, Roy, Gouriprasanna “Interplay of the intermolecular and intramolecular interactions in stabilizing the thione-based copper(I) complexes and their significance in protecting the biomolecules against metal-mediated oxidative damage” Polyhedron Journal, POLYH-D-21-00997R1. Dec. 2021. IF: 3.05
• Ram Krishna Sahu, Binayak Kumar, B C Das, Suresh T Hedau. “Schleichera oleosa up-regulates the expression of BRCA1 and p16 genes, induces apoptosis and inhibits metastasis in breast cancer" Asian Pacific Journal of cancer Prevention, Nov. 2021 (Accepted).  IF: 1.89
• Ragini Singh, Binayak Kumar, Ram Krishna Sahu, Soni Kumari, Chandan Bhogendra Jha, Nahar Singh, Rashi Mathur, Suresh T Hedau “Development of pH-Sensitive Functionalized Metal Organic Framework: In-Vitro Study for Simultaneous Delivery of Doxorubicin and Cyclophosphamide in Breast Cancer. RSC Adv., 2021,11,33723. doi: 10.1039/d1ra04591a. IF: 4.03
• Roy G, Karri R, Chalana A, Kumar B, Jayadev SK. Exploiting the κ2-Fashion Coordination of -donor Ligand L3Se for Facile Hg-C Bond Cleavage of Mercury Alkyls and Excellent Cytoprotection Against Methylmercury-Induced Toxicity. Chemistry. 2019 Jul 12. doi: 10.1002/chem.201902578. PubMed PMID: 31298434. IF: 5.16
• Rai RK, Chalana A, Karri R, Das R, Kumar B, Roy G. Role of Hydrogen Bonding by Thiones in Protecting Biomolecules from Copper(I)-Mediated Oxidative Damage. Inorg Chem. 2019 May 20;58(10):6628-6638. doi: 10.1021/acs.inorgchem.8b03212. Epub 2019 May 8. PubMed PMID: 31067034. IF: 5.44
• Chalana A, Karri R, Das R, Kumar B, Rai RK, Saxena H, Gupta A, Banerjee M, Jha KK, Roy G. Copper-Driven Deselenization: A Strategy for Selective Conversion of Copper Ion to Nanozyme and Its Implication for Copper-Related Disorders. ACS Appl Mater Interfaces. 2019 Feb 6;11(5):4766-4776. doi: 10.1021/acsami.8b16786. Epub 2019 Jan 28. PubMed PMID: 30644707. IF: 10.38
• Kumar B, Agarwal R, Singh A and Sri Krishna Jayadev M. Role of JAK-STAT signaling in Sorafenib resistant HCT-116 cells. Biochem. Cell. Arch. Vol. 17, March 2017. IF: 0.25 
• Agarwal R, Kumar B, Jayadev M, Raghav D, Singh A. CoReCG: a comprehensive database of genes associated with colon-rectal cancer. Database (Oxford). 2016 Apr 25;2016. pii: baw059. doi: 10.1093/database/baw059. Print 2016. PubMed PMID:  27114494; PubMed Central PMCID: PMC4843536. IF: 4.46
• Trehanpati N, Shrivastav S, Shivakumar B, Khosla R, Bhardwaj S, Chaturvedi J, Sukriti, Kumar B, Bose S, Mani Tripathi D, Das T, Sakhuja P, Rastogi A, Bhihari C, Singh S, Gupta S, Kottilil S, Sarin SK. Analysis of Notch and TGF-β Signaling Expression in Different Stages of Disease Progression During Hepatitis B Virus Infection. Clin Transl Gastroenterol. 2012 Oct 4;3:e23. doi: 10.1038/ctg.2012.17. PubMed PMID: 23238065; PubMed Central PMCID: PMC3491533. IF: 4.48
• Trehanpati N, Shrivastava S, Kumar B, Sukriti S, Tripathi DM, Singh S, Gupta S, Kottilil S, Sarin SK. Notch 1 helps differentiate immune cells in acute hepatitis b and with tgf beta regulates foxp3 expression on liver infiltrating lymphocytes in hbv related cirrhosis and hcc. In hepatology 2011 Oct 1 (Vol. 54, pp. 1093A-1094A). Commerce place, 350 main st, malden 02148, ma usa: wiley-blackwell. (Conference Paper). IF. 17.4

Book Chapters

• 1.    Kumar B., Sharma D., Gorantala J., Magani S.K.J. (2020) Small Molecule-Targeted Therapies for GI Cancers: Success and Failures. In: Nagaraju G.P., Peela S. (eds) Novel therapeutic approaches for gastrointestinal malignancies. Diagnostics and Therapeutic Advances in GI Malignancies. Springer, Singapore. https://doi.org/10.1007/978-981-15-5471-1_4.
• 2.    Fayyaz Rasool#, Binayak kumar#, Deepu sharma#, Sri Krishna Jayadev Magani Molecular signaling and its role in Drug resistance in Hepatocellular Carcinomas. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 2. Elsevier publishing house, https://doi.org/10.1016/B978-0-323-98807-0.00006-5. (# Equal Contribution)

Certifications

• Participated in the Faculty Development program on ‘Education 5.0: Constructive alignment in Teaching Learning Practices, Sharda University from 14th to 20th December 2023.

Area of Interest

• Molecular oncology of Breast Cancer
  Research is focused on molecular oncology, exploring molecular mechanisms of developing kinase inhibitors resistance in various cancers that is acquired therapy-resistance. Therapy resistance is being one of the major challenges in cancer management. Here, we develop kinase inhibitor-resistant cells models, explore the molecular mechanisms of therapy resistance by approaching genetic, epigenetic, transcriptomics and proteomics approaches in multi-kinase inhibitor-resistant breast cancer models. Study stem cells behaviors in drug resistant models and their post-transcriptional regulation (miRNAs) targeting potential new drug target and biomarkers for therapeutics and prognostic purposes respectively. My doctoral study was focused to explore molecular changes in regorafenib and sorafenib resistance colorectal cancer. In my ICMR-Postdoct, explored the molecular changes in abemaciclib and palbociclib resistant cell models. Currently looking for the role of stem cell transcription factors in abemaciclib and palbociclib resistance breast cancer cells and their post-transcriptional regulation.